A Phase 2 interventional study of FOLFOXIRI Protocol and Cisplatin injection in Neuroendocrine Carcinoma, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-30.
Sponsored by Centre Hospitalier Universitaire Dijon · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Carcinoma, Neuroendocrine with a site in France — 7 open to participants now, 8 under way, 1 of them phase 3. Carcinoma, Neuroendocrine · France.
Among the 17 studies in Carcinoma, Neuroendocrine with a site in France, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2020, is one of 10 in phase 2, and was the 9th registered.
172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 65 are open to participants now.
Browse Carcinoma, Neuroendocrine studies →7 of the 17 studies in Carcinoma, Neuroendocrine with a site in France are open now. Recruiting first, the newest first:
Intergroupe Francophone de Cancerologie Thoracique · Sites in France
Ages 18+
UNICANCER · Sites in France
Ages 18+
Daiichi Sankyo · Sites in France, United States, Argentina and 15 more countries
Ages 18+
GERCOR - Multidisciplinary Oncology Cooperative Group · Sites in France
Ages 18+
Turning Point Therapeutics, Inc. · Sites in France, United States, Australia and 16 more countries
Ages 12+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 46 Carcinoma, Neuroendocrine studies recruiting now, 29 (63%) set no upper age limit and 10 (22%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 1
First in 2006; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 218 is above the median of 60 across 144 interventional studies indexed under Carcinoma, Neuroendocrine.
Median enrollment 157 across the 16 interventional studies, 90 across the 1 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire Dijon is the lead sponsor of 499 studies on the registry; 103 are open to participants now.
Centre Hospitalier Universitaire Dijon has 1 study filed under Carcinoma, Neuroendocrine — fewer than ten, so there is no comparison to draw.
2 of the studies in Carcinoma, Neuroendocrine with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04268121GERCOR - Multidisciplinary Oncology Cooperative GroupEfficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas | 2027-01 |
| NCT05599984AbbVieStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Carcinoma, Neuroendocrine with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
there is a need for improving chemotherapy regimen for metastatic G3 NEC of GEP and Unknown origin and this goal may be achieved through more "personalized" chemotherapy regimen.the hypothesis is that mFOLFIRINOX regimen could be a good candidate for challenging the platinum-etoposide regimen in patients with metastatic G3 NEC of GEP or unknown origin. Furthermore, in order to get insights in the putative predictive biomarkers of efficacy of these two regimens, an effort toward a precise molecular characterization of these tumors is required in order to be able to define which subgroup of G3 NEC needs to be treated by which chemotherapy regimen. The FOLFIRINEC trial is set up in order to try to answer these questions
Grade 3 poorly differentiated neuroendocrine carcinomas (G3 NEC) are rare diseases. The diagnosis is often done at the metastatic stage and the prognosis is poor. The standard first-line treatment is the platinum-etoposide chemotherapy regimen, mostly based on retrospective studies .With this regimen, response rate (RR) is 40 to 70% but the median progression-free survival is between 4 and 9 months. Disease progression almost always occurs during or just after treatment and median overall survival (OS) is only about 12-15 months for gastro-entero-pancreatic (GEP) NEC with similar efficacy of either cisplatin or carboplatin in the NORDIC study and of 8 to 10 months for pulmonary NEC. After progression, only 40 to 45% of patients will receive a second line chemotherapy which will include 5-fluoro-uracil (5FU) and irinotecan (FOLFIRI or oxaliplatin (XELOX, FOLFOX).This second line treatment can provide around 30% of responses and a median progression-free survival of 4 months. Taken together, these data indicate a major medical need for improving G3 NEC treatments.
Few trials have tried to challenge the standard platinum-etoposide first-line treatment. Clinical trials challenging the platinum-etoposide combination in the first-line setting feasibility has already been demonstrated with paclitaxel-carboplatin-etoposide combination and the cisplatin-irinotecan phase III trials. However, these trials have shown equivalent activities between experimental group and platinum-etoposide regimen. Furthermore, the lack of randomization precluded any definitive conclusion. Therefore, prospective randomized studies aiming at improving first-line chemotherapy remains challenging and clinically meaningful. Currently, the only randomized trial in progress in first line treatment of metastatic G3 GEP NEC compares platinum-etoposide to temozolomide-capecitabine. Other mono-arm phase II studies evaluate carboplatin - nab-paclitaxel and everolimus - temozolomide combinations. FOLFIRINOX is also planned to be evaluated in a mono-arm first or subsequent line setting at Lee. H Moffit Cancer Institute.
Although the second-line treatment studies of metastatic G3 NEC of GEP or unknown origin were retrospective, they have suggested that both irinotecan and oxaliplatin, in conjunction with 5FU can have anti-tumor effect in G3 NEC. In recent years, the intensified chemotherapy regimen FOLFIRINOX, which associates 5FU, oxaliplatin and irinotecan, has shown great efficacy in several digestive cancer such as pancreas or colorectal adenocarcinoma. Tolerance of this regimen has improved over the years with better management and dose adaptations that has led to the development of the mFOLFIRINOX regimen . mFOLFIRINOX could be a good first-line treatment candidate in metastatic GEP NEC because: (i) Oxaliplatin, irinotecan and 5FU have anti tumor effect in metastatic GEP NEC; (ii) trichemotherapy with a potential high RR could be efficient in these chemosensitive cancers; (iii) the degradation of performance status following tumor progression after first-line treatment makes access to a second line uncertain which argue for the use of an aggressive first-line treatment; (iiii) administration on a one-day outpatient basis (day hospital) as well as acceptable and manageable side effects, could have an impact on quality of life in these patients with a poor prognosis. the hypothesis is that the intensive trichemotherapy mFOLFIRINOX, improves the prognosis of patients with metastatic G3 NEC from GEP or unknown primary.
Little is known on the predictive factors of first-line chemotherapy in metastatic G3 NEC and few trials have tried to challenge the platinum-etoposide standard. Among G3 NEC, there are 2 histological subtypes; eg. small cell NEC (SCNEC) and large cell NEC (LCNEC). These two subtypes are treated with the same platinum-etoposide regimen, whatever the primary, although RR seem to differ between SCNEC and LCNEC. This difference has been reported for pulmonary G3 NEC: the RR to platinum-etoposide was 34% in the French phase II trial on LCNEC and 37% in a recent retrospective study, while the RR of SCNEC was 50 to 60% in different reports. Moreover, the difference in RR to platinum based chemotherapy has also been recently reported in a Japanese retrospective study of pancreatic NEC with RR of 68 and 44% for SCNEC and LCNEC respectively.
These results suggest that there could be some biological differences among G3 NEC, which could be responsible for the different responses to treatment and that G3 NEC could be a heterogeneous group of tumors. While pulmonary SCNEC are fairly homogeneous tumors and are characterized by a quasi-constant Rb loss of expression, LCNEC are more heterogeneous. A sequencing study of 45 pulmonary LCNEC samples has shown that 40% of the tumors had a mutational profile which looks like small cell lung cancer (SCLC) while 58% of the tumors had a mutation profile like those found in non-small cell lung cancer (NSCLC) (Rekhtman et al. 2016). According to their molecular profiles, LCNEC could be divided between "NSCLC-like" and "SCLC-like" tumors. "SCLC-like" tumors were characterized by p53 and Rb inactivating mutations while "NSCLC-like" tumors were characterized by p53 inactivating mutations but also KRAS and STK11 mutations like those found in lung adenocarcinomas. Therefore, when considering the pulmonary NEC model, it could be hypothesized that, among LCNEC, some tumors may be "adenocarcinoma-like" and some other may be really "SCNEC-like". This hypothesis is supported by some data from digestive tract G3 NEC. Rb loss of expression is found in 100% of SCNEC of the colon versus 31% of LCNEC of the colon; Rb loss is also found in 89% of SCNEC versus 60% of LCNEC of the pancreas . These data seem to parallel the pulmonary NEC data and suggest that G3 NEC, especially LCNEC, is a heterogeneous group of tumors with some of them being biologically very close to SCNEC with Rb loss and others being more biologically close to adenocarcinoma. G3 SCNEC are probably more homogeneous but some heterogeneity is also possible within this group because the pathological diagnosis of "large"versus "small cell" is challenging. This has led to the hypothesis that LCNEC could arise from different cell of origin, i.e; from neuroendocrine precursors and/or from trans-differentiation of adenocarcinoma cells as already described in prostate and lung cancer while SCNEC would represent the bona fide poorly differentiated NEC.
Taking together the putative biological heterogeneity of G3 NEC and the need, in clinical practice, for more effective chemotherapy regimen, it can be hypothesized that a more "tailored" chemotherapy regimen is needed for G3 NEC patients. This is supported by the retrospective analysis from the Dutch registry of pulmonary NEC which have suggested that "NSCLC-like" chemotherapy regimen without pemetrexed were more effective than "SCLC-like" chemotherapy regimen for the treatment of pulmonary LCNEC. Moreover, the same group has recently reported that the better efficacy of "NSCLC-like" chemotherapy was observed for pulmonary LCNEC without Rb mutation (the so-called "NSCLC-like" tumors in the Rekhtman et al study) while Rb mutated LCNEC did not have significantly different response to "SCLC-like" and "NSCLC like" chemotherapy regimens. This has also been shown in pancreatic LCNEC with a RR to first-line platinum-based chemotherapy of 80% in case of Rb loss of expression, and 38.4% in case of retained Rb expression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Grade 3 neuroendocrine carcinoma or high grade MiNEN with a grade 3 poorly differentiated neuroendocrine carcinoma component ≥30% of gastro-entero-pancreatic or unknown primary
Exclusion Criteria:
Grade 3 well differentiated neuroendocrine tumor according to WHO 2017 classification
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
mFOLFIRINOX will be administered once every 14 days for up to 12 cycles. One cycle consists of 14 days (2 weeks) with injection on D1 of each cycle (D1=D15). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
Drug: FOLFOXIRI Protocol
Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
Drug: Cisplatin injection
Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
Also known as: modified FOLFIRINOX
Cisplatin 100 mg/m2, IV infusion over 3 hours or Carboplatin AUC 5, IV infusion over 30 minutes on day 1 \[the dose of carboplatin will be determined for each cycle using the Calvert's formula (carboplatin dose (mg) = target AUC 5 x estimated glomerular filtration rate (eGFR, mL/min) + 25)\]; • Etoposide 100 mg/m² IV infusion over 1 hour on day 1,2 and 3
Also known as: Platinum - Etoposide, carboplatin injection
median of progression free survival
The primary endpoint is the median of progression-free survival. PFS is defined as the time interval between date of randomization and date of the first radiological progression (according to RECIST 1.1) or death due to any cause, whichever occurs first, according to investigator. Patient alive without progression will be censored at date of last follow-up visit.
Time frame: 7.5 MONTHS
Progression-free survival (PFS)
time interval between date of randomization and date of the first radiological progression (according to RECIST 1.1) or death due to any cause, whichever occurs first, according to the centralized review.
Time frame: 9 MONTHS
Overall survival
OS is defined as the time interval between date of randomization and date of death (whatever the cause). Patients alive will be censored at date of last news.
Time frame: 15 MONTHS
Best objective response rate
The best objective response rate is defined as the proportion of patients with an objective response (Complete response (CR) + Partial response (PR)) at any evaluation during the treatment, according to RECIST 1.1.
Time frame: 8 weeks after randomization
Safety and tolerability profile: percentage of patients who experienced toxicities
Safety profile is defined as the percentage of patients who experienced toxicities and grading of these toxicities. Toxicities will be presented as the number of patients presenting at least an episode of toxicity by maximum grade. Toxicity grading will follow NCI-CTC V4 guidelines
Time frame: 24 months after randomization of the last subject
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2020 (actual). Primary completion is estimated for Sep 2029, 108 months after the start.
Of 43 phase 2 interventional studies under Carcinoma, Neuroendocrine, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 91. This study's planned 108 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: FOLFOXIRI protocol
Centre Hospitalier Universitaire Dijon →